A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

This study is conducted as part of the local risk management plan to collect and understand the following information about the surveillance drug under the real-world clinical practice settings. To evaluate the safety of Beyfortus in Korean children who received Beyfortus under the real-world clinical practice settings per the approved indication. The investigator will decide whether to enroll participants if they determine that administering Beyfortus according to current practice can provide clinical benefits in terms of safety and efficacy Participants will be followed-up for 180 days after Beyfortus administration.

NCT Number	NCT07200206
Lead Sponsor	Sanofi
Conditions	Respiratory Syncytial Virus
Enrollment	3,000 participants
Start Date	2025-10-02
Primary Completion	2029-09-26 (estimated)
Study Completion	2029-09-26 (estimated)
Updated on ClinicalTrials.gov	2025-12-03